Prostate Cancer

Latest News


Latest Videos


CME Content


More News

<p>Approximately four years after the FDA approval of two powerful new oral androgen-targeting agents for metastatic castration-resistant prostate cancer, an analysis&nbsp;heightened&nbsp;clinical awareness of the&nbsp;potential for both under-treatment and over-treatment with abiraterone acetate, as well as potential drug-drug interactions with both abiraterone acetate and enzalutamide.</p>

<p>Charles J. Ryan, MD, professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, discusses the role of abiraterone acetate&nbsp;in the treatment of patients with prostate cancer, and the questions that remain about its use.</p>

A study of apalutamide (ARN-509) in patients with high-risk, localized, or locally advanced prostate cancer who are receiving primary radiation therapy is hoping to reduce the risk of metastasis and death from prostate cancer for these high-risk patients, according to the study&rsquo;s global principal investigator, Howard M. Sandler, MD.